The company's proprietary drug discovery platform focuses on identifying novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. Plexium's aim is to develop a wide range of monovalent target protein degraders that go beyond the limitations of PROTACs and cereblon imids, offering boundless possibilities for true drug-like protein degraders. Their pipeline includes molecular glues and monovalent degraders, with applications across various therapeutic areas such as cancer and neurodegeneration. By redirecting ligases to targets of interest or directly binding to them, Plexium's therapeutics provide an improved approach to combat cancer and inflammatory diseases.